Work

A Phase II Trial of Acalabrutinib in Combination with PI3Kδ Inhibitor Umbralisib and the Anti-CD20 Antibody Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

Year: 2022

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2022-159805

Authors: Alexey V Danilov, Alexandra Muir, Ivana Melgar, Sandrine Puverel, Peter Sportelli, Hari P. Miskin, Lu Chen, Geoffrey Shouse

Institutions: City of Hope, City Of Hope National Medical Center, TG Therapeutics, Inc. (United States)

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310108960

FWCI: 0.142

Cites:

Cited by: 1

Related to: 10